Accro Bioscience Doses First Patient in AC-101 Phase IIb UC Trial
New York and Suzhou, China – September 20, 2026 -- Accro Bioscience Inc. has dosed its first patient in a Phase IIb trial testing AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).
Trial spans roughly 50 clinical sites with three treatment arms
The multicenter, double-blind, placebo-controlled study is designed across approximately 50 clinical sites and includes two AC-101 dose cohorts plus a placebo control arm. The primary endpoint is clinical remission rate at Week 12, with exploratory endpoints covering histologic remission and long-term maintenance of clinical and histologic remission.